Home Latest Articles
Latest Articles
  • Jun WANG, Yuejing MU, Ying HAN, Langui XIE, Zhen ZHANG, Xing HUANG
    Chinese Journal of Pharmaceuticals. 2026, 57(8): 990-994.
  • Xing HUANG, Langui XIE, Zhijie JIANG, Jiaming WEI, Xiaoming LIN, Ying HAN
    Chinese Journal of Pharmaceuticals. 2026, 57(8): 995-1001.
  • Hongfen MAO, Hao YU, Taoxi LIN, Lu HUANG
    Chinese Journal of Pharmaceuticals. 2026, 57(8): 1002-1008.
  • Yan MA, Bo LI, Guanxiang LUO, Chen GUO
    Chinese Journal of Pharmaceuticals. 2026, 57(8): 1009-1015.
  • Mingjie Qin
    Chinese Journal of Pharmaceuticals. 2026, 57(8): 1016-1021.
  • Junjun DONG, Kuaile LIN, Zhengyan CAI
    Chinese Journal of Pharmaceuticals. 2026, 57(7): 743-755.

    Targeted protein degradation technology eliminates pathogenic target proteins via two endogenous degradation pathways, namely the ubiquitin-proteasome system and the lysosomal system, and has rapidly emerged as a promising drug discovery in recent years. The lysosomal degradation pathway exhibits unique developmental advantages owing to its capability to degrade a broad spectrum of substrates including intracellular proteins, extracellular proteins and protein aggregates. This paper systematically reviews the latest research advances of lysosome-based targeted protein degradation technologies. It comprehensively elaborates on the mechanisms, core advantages and existing challenges of novel lysosomal degraders corresponding to the endosome - lysosome and autophagy - lysosome pathways, including lysosome-targeting chimeras, autophagy-targeting chimeras, autophagosome-tethering compounds, and chaperone-mediated autophagy targeting chimeras. Furthermore, the future application prospects of these technologies in innovative drug research and development are highlighted.

  • Hongxia TANG, Jiawei LIANG
    Chinese Journal of Pharmaceuticals. 2026, 57(7): 756-763.

    Vaborbactam(1) is a novel boron-containing β-lactamase inhibitor. Used in combination with meropenem, it can treat complicated urinary tract infections. This combination therapy exhibits a favorable safety profile and robust clinical efficacy alongside substantial market demand, making research into its industrial synthetic routes highly significant. This review summarizes the currently reported synthetic routes of 1. One category of routes firstly utilized chiral enzymatic resolution to obtain the enantiomer tert-butyl (R)-3-hydroxy-4-pentenoate, followed by a Matteson reaction to construct the chiral boronate intermediate. Adopting continuous flow technology for the Matteson reaction can improve efficiency and safety. Another category of routes utilizes Ellman chiral imines for asymmetric borane addition to highly selectively generate the chiral boronate intermediate, which then undergoes deprotection and cyclization to yield the target 1. These routes feature readily available starting materials, mild conditions, as well as safety and environmental friendliness.A NiH-catalyzed hydroamidation route can prepare the chiral boronate intermediate from alkenyl boronic esters in a single step without the need for chiral auxiliaries or precious metal catalysts, but it is not suitable for industrial production. This paper compares and analyzes the advantages and limitations of various synthetic routes, and proposes that the synthesis of compound 1should be optimized toward fewer reaction steps, higher yields, milder reaction conditions and greener manufacturing processes.

  • Jiabin GUO, Chengfu CHEN, Naihua ZHANG, Wei WANG, Guimin ZHANG
    Chinese Journal of Pharmaceuticals. 2026, 57(7): 764-767.

    Acipimox(1) is mainly used for the treatment of hyperlipidemia. In this study, 2,5-dimethylpyrazine(3)was used as the starting material, and a continuous flow reaction scheme in series was adopted instead of the batch reaction to obtain 1. By taking advantage of the high heat and mass transfer efficiency of the continuous flow microreactor, the selectivity of the reaction was improved. By taking advantage of the small liquid holding capacity of the continuous flow microreactor, the safety of the reaction was enhanced, and the continuous flow total synthesis of 1was ultimately achieved.The total yield was 86.94%(based on 3), and the purity was 99.24%. This technology not only significantly enhances production efficiency and safety, but also features a small equipment footprint, low renovation costs, and a green and pollution-free production process, resulting in high economic and social benefits.

  • Anguo ZHU, Naihua ZHANG, Caijiao WU, Zhongkui ZHANG, Guimin ZHANG
    Chinese Journal of Pharmaceuticals. 2026, 57(7): 768-771.

    An improved synthetic process for the key intermediate of prucalopride succinate, 1-(3-methoxypropyl)-piperidin-4-amine(1), was reported in this study. Commercially available 4-hydroxypiperidine(2) was reacted with acetonitrile in the presence of calcium bisulfate to afford 4-N-acetylpiperidinamine(3) through a Ritter reaction. Then, compound 3was alkylated with 1-bromo-3-methoxypropane to give 4-N-acetyl-1-(3-methoxypropyl)piperidinamine(4).Finally, the acetyl group of 4underwent deacetylation catalyzed by boron trifluoride diethyl etherate, to afford the target compound 1in an overall yield of 78.7%(based on 2) and a purity of 99.86%. The improved process offers advantages of simple operation and mild conditions, and has been validated at kilogram-scale.

  • Shimin SUN, Lili ZHAO, Zhong LIU, Guimin ZHANG, Zhongsong ZHU
    Chinese Journal of Pharmaceuticals. 2026, 57(7): 772-781.

    Tumor necrosis factor receptor 2(TNFR2) is highly selectively expressed on tumor cells and regulatory T cells, and represents an important target for tumor immunotherapy. Current TNFR2-targeted drugs encounter developmental bottlenecks such as off-target cross-reactivity and species-specific differences. In this study, a recombinant human TNFR2 monoclonal antibody termed anti-hTNFR2 mAb was generated, and its in vitro and in vivo activities were systematically evaluated. First, through murine immunization, hybridoma screening, complementarity determining region grafting-mediated humanization, and affinity maturation, an anti-hTNFR2 mAb was obtained. After expression and purification, its efficacy was investigated through in vitro activity assays and in vivo studies using mouse solid tumor models.The results showed that the anti-hTNFR2 mAb exhibited high binding affinity(KD=1.18×10-10 mol/L) and blocking activity(IC50=0.037 4 nmol/L), both surpassing those of the positive control antibody 1-H10. Antibody-dependent cell-mediated cytotoxicity of anti-hTNFR2 mAb was quantified via fluorescence-activated cell sorting, yielding an EC50 of 0.078 2 nmol/L, which was superior to that of 1-H10(0.140 2 nmol/L). Collectively, the antibody exhibited significant anti-tumor effects in mice. At a dose of 10 mg/kg, the tumor growth inhibition rate reached 99.1%, outperforming that of 1-H10 (93.9%).

News